Labcorp Launches Companion Diagnostic for Amgen’s Newly-approved Lung Cancer Therapy

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp® (NYSE: LH), a leading global life sciences company, today announced the availability of therascreen® KRAS PCR Mutation Analysis, a companion diagnostic to identify patients with non-small cell lung cancer (NSCLC) who are eligible for treatment with LUMAKRAS™ (sotorasib), a new treatment option developed by Amgen. Labcorp’s oncology...

Click to view original post